Price Traction

It is sometimes hard to see FTT price performance.
Where the world markets are at record highs, speculative capital is pouring in many initiatives, ventures get easily financed for their projects, demands for shares are generally very strong, FTT is still unable to get traction for its current new face and ongoing projects.
The current valuation of less than 50 million A$ is a misery for a biotech with a billion dollar sales potential.

It looks like previous management has caused some really serious damage to the company.
In the past with a much less valuable pipeline and just a device European Union protocol, the company was worth more than 100 million A$. The expected sales were ridiculous even because the device application was far from originating actual sales.

The Australian private capital is not willing to speculate on the ongoing US clinical trial.
The US capital is absent even if there is a US protocol.
Sure if the company would had been US listed as many Israeli companies do, we would have had a much better valuation.

OK. All is blah, blah, but the current valuation is very indicative. Let's see the next six months what this company can actually deliver. But, even delivering there is no guarantee that the company will over-perform in the financial market.

Watching...